Retatrutide: A Research Overview of Triple Hormone Receptor Agonism and Metabolic Studies
Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly that has become one of the most discussed compounds in metabolic research literature. Its defining characteristic is simultaneous activity at three hormone receptors: glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This triple agonism distinguishes retatrutide mechanistically from all previously […]